Transaction details
Keith Woods, the Chief Operating Officer of Scholar Rock Holding Corp (NASDAQ: SRRK), sold 10,220 shares of the company’s common stock on April 16, 2026. The transaction generated approximately $506,651 in proceeds, with individual shares sold at a price of $49.5745. At the time of the sale the share price sat close to the company’s 52-week high of $51.62, after the stock recorded a 55% gain over the previous 12 months.
Reason for the sale
The disposition was a "sell to cover" required to satisfy tax withholding obligations associated with the vesting of restricted stock units (RSUs) on April 15, 2026. Under Scholar Rock’s equity incentive plans, the reporting person is required to fund tax withholding through a brokerage firm designated by the company. The company has characterized this particular transaction as non-discretionary - it was executed solely to meet the tax obligation and does not represent an independent decision by Mr. Woods to reduce his stake.
RSU grant and vesting schedule
The RSUs that triggered the tax withholding were originally granted on April 27, 2025. Those awards vest on an annual basis over four years and are subject to Mr. Woods maintaining his service relationship with the issuer. The sale on April 16, 2026, therefore relates directly to the first vesting event under that grant.
Post-transaction ownership
Following the sale, Mr. Woods’ direct ownership totals 620,055 shares. That aggregate comprises 48,034 shares of common stock, 122,021 RSUs subject to time-based vesting conditions, and 450,000 RSUs that carry both performance- and time-based vesting conditions.
Valuation note
According to InvestingPro analysis cited in company reporting, Scholar Rock’s stock currently appears overvalued relative to its Fair Value. The sale took place while the market price was trading close to the 52-week high, a backdrop the valuation note highlights.
Regulatory and analyst context
Separately, Scholar Rock resubmitted its Biologics License Application (BLA) for apitegromab, a potential treatment for spinal muscular atrophy, to the U.S. Food and Drug Administration. The resubmission includes two fill-finish partners, one of which is Catalent Indiana LLC, now part of Novo Nordisk, alongside a second U.S.-based facility. The resubmission followed a positive Type C meeting with the FDA and seeks to address observations that arose from a previous inspection of the Catalent Indiana site.
Analysts have responded favorably to the regulatory update. Jefferies raised its price target for Scholar Rock to $57 and maintained a Buy rating. BofA Securities increased its price target to $58 while also maintaining a Buy recommendation. Truist Securities reiterated a Buy rating with a $55 price target after Roche halted development of a competing drug, emugrobart, citing inconsistent results. The company expects the resubmission to lead to a Prescription Drug User Fee Act (PDUFA) date in late September 2026.
What this means for investors
The insider sale here was procedural rather than discretionary, executed to meet tax withholding obligations tied to RSU vesting. At the same time, the company’s regulatory actions and subsequent analyst reactions have shaped market sentiment, with price targets raised by multiple firms and a clarified regulatory pathway for apitegromab reflected in the expected late-September 2026 PDUFA timeline.
Note on sources and data
All transaction details, RSU grant and vesting information, ownership totals, valuation commentary, regulatory filing activity, analyst ratings, and the PDUFA timing are reported as stated in company disclosure and analyst notes.